TABLE 3.
Summary of effect sizes for the physiological and psychosocial QoL outcomes
| Study | Design, treatment | Effect sizes | |
|---|---|---|---|
| Physiological outcomes | Psychosocial QoL outcomes | ||
| Battaglini32 | RCT, COMB-S/R/C | Strength 1.39 | Fatigue Wk 8, .4; Wk 11, .17; Wk 15, .92; Wk 21,.43 |
| Battaglini20 | RCT, COMB-S/C | LBM Wk 8, .3; Wk 11,.47; Wk 15, .55; Wk 21, .9 BF% Wk 8, .31; Wk 11, .5; Wk 15, .53, Wk 21,.98 Strength 1.4 | NA |
| Cadmus29 | RCT, MIX – R/C | NA | Happiness .49 Fatigue −.1 FACT-G .30 SF-36 MH .28; SF-36 Soc .58; SF-36 VIT .01; SF-36 ROLE .33; SF-36 PHY .19; SF-36 Pain .42; SF-36 GEN .16; SF-36 ROLP .45 |
| Chandwani28 | RCT, R | NA | Fatigue post, 1.0; 1-month post, 1.4; 3-month post 2.0; 6-month post, 1.13 Depression post, 1.3; 1-month post, −1.4; 3-month post 0.93; 6-month post, 0.90 QoL post, 1.5; 1-month post, 2.1; 3-month post 3.0; 6-month post, 1.8 Sleep quality post, 2.8; 1-month post, 2.1; 3-month post 3.2; 6-month post, 2.17 |
| Courneya22 | RCT, C | Chest press strength RE, .9; AE, .34 Leg press strength RE, .7; AE, .25 VO2peak RE, .21; AE, .06 BW RE, .09; AE, .07 BF% RE, 0; AE, 0 FM RE, .05; AE, .04 LBM RE, .21; AE, .12 | FACT-A RE: mid, .01, post, .3; AE: mid, −.007; post, .33 SE RE: mid, −.24; post,−.18; AE: mid, .00; post, .24 Anxiety RE: mid, .42; post, .45 AE: mid, 0.46; post, .49 Depression RE: mid, .12; post, .32; AE: mid, .06; post, +.32 |
| Dolan23 | RCT, C | Hb RE, 1.7; AE, 1.1 VO2 RE, .21; AE, .06 | NA |
| Hornsby16 | RCT, C | RHR .55 VO2 .35 Vent .74 CO 1.0 LVEF% .13 | FACT-B, .22 FACT-G,.16 |
| Husebø25 | RCT, MIX – R/C | 6MWT post,−.2; FU, .31 MET post, .18; FU, .43 | Fatigue post, −.41; FU, −.02 |
| Hwang26 | RCT, R | NA | QoL, .63 QoL Overall Health, .36 QoL Physical, 1.67 QoL Psychological, .48 QoL Social, .54 QoL Environmental, .11 |
| Kim30 | RCT, MIX-R/C | RHR .5 MHR .26 RBP .24 MBP .41 VO2 .38 | NA |
| Mock31 | RCT, MIX – R/C | 12MWT Hi, .33; Lo, .02 ALRS Hi, .76; Lo, .25 | Fatigue Hi, 1.41; Lo, .48 |
| Mock19 | RCT, MIX – R/C | PF Hi, .2; Lo, .39 12MWT Hi, .57; Lo, −.20 PA Hi, .40; Lo,−. 14 | Fatigue Hi, −.22; Lo, −70 |
| Schwartz24 | RCT, C | 12MWT AE, .79; RE, .13 OHP strength AE, .24; RE, .21 SR strength AE, .61; RE, .5 Leg ext strength AE, .5; RE, .45 | NA |
| Vadiraja27 | RCT, R | Cortisol 6 am, .68; 9 am, .46; 9 pm, .19 | Anxiety .87 Depression .91 Stress 1.01 |
| Wang17 | RCT, MIX – R/C | NA | FACT-GTP1 .15; TP2,−.12; TP3, .65 FACIT-F TP1 .38; TP2, −.15; TP3, .66 PSQITP1 .19; TP2, .40; TP3, .40 ESES TP1 .48; TP2, .68; TP3, .64 GLTEQ TP1 .96; TP2, .87; TP3, 1.36 |
| Yang18 | RCT, C | MET 6 mo, .64; 12 mo, .6 | Fatigue severity 6 mo, −.5; 12 mo, .56 Fatigue intensity 6 mo, −.85; 12 mo, −.78 POMS-SF 6 mo, .68; 12 mo, .59 |
| Schmidt21 | RCT, C | NA | Total fatigue .015 Physical fatigue .02 Affective fatigue . 11 Cognitive fatigue . 18 QLQ-C30 Global .01 CES-D Depression .008 |
6MWT, 6-minute walk test; 12MWT, 12-minute walk test; ALRS, activity level rating scale; BF%, body fat percentage; BW, body weight; CES-D, Center for Epidemiologic Studies Depression Scale; CO, cardiac output; EDV, end diastolic volume; ESES, Exercise Self-Efficacy Scale; ESV, end systolic volume; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FACT, Functional Assessment of Cancer Therapy (A, Anemia; B, Breast; G, General) FM, fat mass; FU, follow-up; GLTEQ, Godin and Shepherd’s Leisure Time Exercise Questionnaire; Hb, hemoglobin; LBM, lean body mass; leg ext, leg extension; LEVF%, left ventricle ejection fraction; MBP, max blood pressure; MET, metabolic equivalent task; MHR, max heart rate; na, not applicable; O2 pulse, oxygen pulse (mLO2/beat); OHP, overhead press; PA, physical activity, PBP, peak blood pressure; PF, physical function; PHR, peak heart rate; POMS-SF, Profile of Mood State-Short Form; PSQI, Pittsburgh Sleep Quality Index; QLQ-C30, Quality of Life Questionnaire-Core 36; RBP, resting blood pressure; RHR, resting heart rate; SE, self-efficacy, SF-36, Short Form Health Survey (GEN, general health; MH, mental health; PHY, physical functioning; PAIN, bodily pain; ROLE, role limitations-emotional; ROLE, role limitations-physical; SOC, social functioning; VIT, vitality); SR, seated row; Vent, ventilation (LO2/min); VO2, oxygen consumption;